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in 10,000 inhabitants. Although individually rare, together, rare diseases affect
significant part of the population. Therefore, patient access to orphan medicines
is receiving increasing political attention in the EU. The objective of our study
was to determine the access to orphan medicines in Serbia. METHODS: Serbian
Reimbursement List has been reviewed and identified orphan medicines were
crossed with the List of orphan drugs in Europe, published in July 2011, available
from Orphanet. The analysis of regulatory traits was based on a review of official
documents setting out legislation regarding rare diseases and orphan medicines
in Serbia. RESULTS: Only 6.5% (4 out of 61) of authorised orphan medicines in
Europe with prior orphan designation and 25.0% (17 out of 68) without prior
orphan designation were available and reimbursed in Serbia. According to the
first level of the ATC Classification System, most of reimbursed orphan
medicines belonged to the group L – ‘Antineoplastic and immunomodulating
agents’. It is estimated that there are approximately 500,000 patients suffering
from rare diseases in Serbia. Although the National register for rare diseases
does not exist, the Law on Health Care provides for the forming of the official
centres of reference for rare diseases that have the obligation of diagnosing,
treatment and patient counseling, but also of creation of National register.
Neither policy measures nor research incentives for rare diseases exist in Serbia.
CONCLUSIONS: The low share of reimbursed orphan drugs in Serbia may be due
to incomplete compliance with legislation of EU and existence of domestic
procedure for authorisation. The EU policy on treatment of rare diseases
facilitate the penetration of orphan drugs on the EU market, but apparently there
is also considerable budget impact on the availability of orphan medicines.
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OBJECTIVES: The United States (US) and the European Union (EU) implemented
regulations for encouraging the development of drugs for rare diseases. Criteria
for Orphan designation is generally based on the number of patients affected by
the disease (<200,000 US patients and <5 in 10,000 EU patients). The EU also
requires that a satisfactory alternative treatment is not available or that the new
drug is significantly better than drugs currently marketed. We examined the
characteristics of orphan drug (OD) designations and approvals by the US Food
and Drug Administration (FDA) and the European Medicines Agency (EMA)
between 2000 and 2011. METHODS: Data for orphan designations and approvals
were extracted from the FDA and EMA online databases for the period 2000-2011.
Data were updated to September 14, 2012. The time for OD designation to
approval was estimated. Descriptive analysis, chi-square test, and group
comparison t-tests were used in the analysis. RESULTS: The FDA granted 1558
orphan designations for 1133 different products, and 149 approvals (9.6% of
designated products), and the EMA 935 designations for 639 different products
and 88 (9.4%) approvals during the study period. The time from OD designation
to approval was 2.74±2.39 years in the FDA and 3.31±1.99 years in EME (p<0.05).
EMA approved a larger number of designations (15.2%) than the FDA (12.3%) for
the 569 products designated by both agencies; 67% of these products were first
designated by the FDA and 78% of the 50 products approved by both agencies
were approved first by EMA (p<0.001). CONCLUSIONS: The EU had more
restrictive criteria for orphan designation and significantly longer approval
times, less orphan designations, and fewer product approvals than the US.
Harmonization of the Orphan drug regulatory processes of FDA and EME could
result in improved access to ODs in the US and the EU.
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OBJECTIVES: Opioid abuse is a significant public health problem in the United
States, with opioid-related overdoses accounting for over 16,500 deaths per year.
In addition, opioid abuse imposes a significant economic burden due to
increased health care utilization and costs. This study calculates updated, payerspecific, excess medical costs of diagnosed opioid abuse among commerciallyinsured, Medicaid, and Medicare patients with recent prescription opioid (RxO)
use. METHODS: Using de-identified Truven MarketScan medical and pharmacy
claims data for commercially-insured, Medicaid, and Medicare patients, we
examined the excess costs of diagnosed opioid abuse among patients with at
least one pharmacy claim for an RxO, 2009-2011. Diagnosed abusers were
identified using ICD-9 diagnosis codes for opioid abuse/dependence and were
matched to non-abusers using propensity score methods. Medical costs were
calculated over a 12-month period around the index date, which was the date of
the first abuse diagnosis for abusers and the date of a random medical claim for
non-abusers. Costs reflected payments by insurers as well as out-of-pocket
patient costs, measured in 2011USD. The excess costs of diagnosed opioid abuse
were calculated as the difference in costs between abusers and non-abusers
following matching and included inpatient, emergency room (ER), and outpatient
services. RESULTS: A total of 2510 commercially-insured, 536 Medicaid, and 268
Medicare patients with diagnosed opioid abuse were matched to non-abusers.
The annual per patient excess medical costs associated with diagnosed opioid
abuse were $9,456 (p<0.001) for commercially-insured patients, $11,501 (p<0.001)
for Medicaid patients, and $10,046 (p<0.001) for Medicare patients. Inpatient

costs accounted for 63.0%-78.6% of total excess medical costs, and ER costs
accounted for 5.6%-12.6% of total excess medical costs. CONCLUSIONS: The
excess medical costs of opioid abuse are substantial and reveal a consistent
pattern across payers. These estimates are comparable to prior research,
suggesting opioid abuse continues to impose significant economic burden.
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OBJECTIVES: Opioids, generally recommended as second- or third-line agents for
neuropathic pain (NeP), are commonly used. This study characterized opioid and
antiepileptic drug (AED) utilization among patients with NeP associated with
diabetic peripheral neuropathy (DPN), HIV, spinal cord injury (SCI), chronic lowback pain (CLBP), post-trauma/post-surgery (PTPS), and small-fiber involvement
(SF) stratified by pain severity (mild, moderate, severe). METHODS: Data were
from an observational study of NeP patients recruited during routine visits with
primary-care or specialty physicians. Subjects completed a one-time
questionnaire, and investigators completed a case report form based on a 6month retrospective chart review. Pain severity was based on the Brief Pain
Inventory average pain score. RESULTS: A total of 624 subjects were enrolled:
71.8% were white; 55.4% were male; mean age was 55.5±13.7 years; with a mean
of 7.8±6.8 years since NeP diagnosis. The proportion of patients with each NeP
indication was similar (16.0%-17.9%). Pain severity was mild, moderate, and
severe in 17.6%, 47.6%, and 33.2%, respectively. The most frequently used NeP
medications over the past 6 months were opioids (53.0%) and AEDs (49.0%),
ranging from 33.0% (DPN) to 81.1% (CLBP) for opioids, and 28.3% (CLBP) to 64.1%
(SCI) for AEDs. Overall, AED use remained unchanged across pain severity
categories (46.4%-50.5%), while opioid use increased significantly with greater
pain severity: 28.2% mild, 53.2% moderate, 65.2% severe (p<0.0001). Opioids were
used by substantial proportions of patients across all pain severity levels
including 33.3% in SCI, 50.0% in CLBP, and 71.4% in PTPS. Except for DPN, strong
short-acting opioids were the most frequently used opioid class, ranging from
14.3% in DPN to 55.7% in CLBP. CONCLUSIONS: Patterns of opioid use observed in
this study were not fully consistent with published guidelines; opioid use was
common across six different chronic NeP conditions and did not appear to be
reserved for more severe pain patients.
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OBJECTIVES: Evaluation of measures of medication-taking behavior is
uncommon with infusible pharmacologic agents. This study evaluated
persistence and adherence measures from utilization data on the infusible antiinflammatory biologic infliximab. METHODS: Patients were identified through
the electronic health records (EHR) with ICD-9 diagnoses of rheumatoid arthritis
(714.xx), psoriatic arthritis (696.xx), ulcerative colitis (556.xx), or Crohn’s disease
(555.xx). Incident infliximab-treated patients between January 1, 2007 and June
30, 2011, ≥18 years of age, with ≥1 maintanence dose were included. Infliximab
dosing data were extracted from medical chart review and the EHR. We
employed Kaplan-Meier (KM) analyses to estimate median time to treatment
discontinuation and Cox regression to evaluate factors associated with
discontinuation. Medication possession ratio (MPR) was calculated as sum of
prescribed infusion frequency intervals divided by days from first infusion to last
infusion. Compliance was defined as MPR ≥0.80. Proportion of days covered was
also explored (data not shown). Sensitivity analyses were performed for various
definitions of “treatment gap” and “discontinuation”. Analyses are shown for gap
of ≥90 days. For all test statistics, a p-value <0.05 was considered statistically
significant. RESULTS: We identified 122 patients meeting study inclusion criteria.
Mean age of patients was 45 years and 61% were female. KM estimated a median
treatment duration of 23 months and adjusted Cox regression identified African
Americans at significantly greater risk for treatment discontinuation than
Caucasians (hazard ratio: 4.95; 95% confidence interval: 1.11, 22.05; P=0.036). A
total of 100 patients had a calculable MPR, mean and median MPR were 0.937 and
0.956, respectively, with 93% of patients compliant with treatment. Sensitivity
analyses showed varied results depending on definitions. CONCLUSIONS:
Patients receiving infliximab were overall compliant with therapy during a
median of 23 months of treatment. Underlying definitions used with MPR and
KM are important, and should be clinically meaningful and transparent.
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